September 6-7, the Food and Drug Administration (FDA) and the American Society of Clinical Oncology (ASCO) are holding a free virtual workshop ondose optimization, a critical issue in oncology and in improving the quality of life for patients with cancer. This timely FDA-ASCO workshop will bring together thought leaders and others from academia, industry, regulatory agencies, and patient groups to discuss challenges and opportunities to improve dose selection for patients, specifically for combination therapies.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Senate Appropriations Committee on July 27 passed the Labor, Health and Human Services, Education, and Related Agencies FY 2024 spending bill, which includes $47.8 billion in funding for the National Institutes of Health (NIH), $7.38 billion for the National Cancer Institute (NCI) and $1.5 billion for the Advanced Research Projects Agency on Health (ARPA-H).
A statement from Everett E. Vokes, MD, FASCO, Chair of the Board, Association for Clinical Oncology, follows:
ASCO is continuing to collaborate with State Affiliates and outside stakeholders to raise awareness and facilitate implementation of the CLINICAL TREATMENT Act, which requires all states and territories to cover and reimburse routine costs of care for treating a Medicaid enrollee who is participating in a qualifying clinical trial.
Dr. Brian Persing, a medical oncologist and hematologist in Mobile, Alabama and member of the Association of Clinical Oncology (ASCO), the world’s leading professional organization representing nearly 45,000 oncology professionals, will testify before the House Appropriations Subcommittee on Labor Health and Human Services and Education today in support of increased federal funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control. He will also advocate for robust funding of the Advanced Research Projects Agency for Health (ARPA-H).
The Association for Clinical Oncology (ASCO) is urging lawmakers to prioritize reducing drug shortages, combatting tobacco use, and improving diversity in research as they review funding requests for fiscal year 2024.
ASCO outlines the National Cancer Institute's National Cancer Plan and what it means for progress in cancer care, treatment, and access.
On March 7, Association for Clinical Oncology (ASCO) volunteers joined more than 85 representatives of One Voice Against Cancer (OVAC) on Capitol Hill for a lobby day in support of federal funding for medical research.
Today President Biden released his proposed Fiscal Year (FY) 2024 federal budget with an emphasis on increased funding for medical research and expanded access to health insurance.
“ASCO applauds President Biden’s focus on ‘ending cancer as we know it’ during the State of the Union address. We continue to urge the president to keep cancer care and research as top national priorities and are pleased with his plans to advance efforts to strengthen the Cancer Moonshot, improve cancer clinical trials, and foster breakthroughs through the Advanced Research Projects Agency for Health (ARPA-H).”
Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published today in JCO Oncology Practice.